<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817034</url>
  </required_header>
  <id_info>
    <org_study_id>2018P002053</org_study_id>
    <nct_id>NCT03817034</nct_id>
  </id_info>
  <brief_title>Multimodal Analgesia</brief_title>
  <official_title>Multimodal Analgesia for the Reduction of Postoperative Opioid Consumption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are performing this research study to investigate the efficacy of local
      infiltration of the surgical wound combining dexmedetomidine, ropivacaine, and ketorolac
      (treatment group) versus the current standard of care (historical control group), for
      post-operative pain management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During this research study, patients recommended for a rectus sheath block during surgery
      will receive a novel combination of non-opioid drugs. Data from the treatment group will be
      compared to surgical outcomes of a historically matched control group to investigate the
      ability of this drug combination to reduce post-operative pain and post-operative opioid
      consumption.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in post-operative opioid consumption</measure>
    <time_frame>48 hours</time_frame>
    <description>Decreased post-operative opioid consumption associated with use of multimodal analgesia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in post-operative pain scores</measure>
    <time_frame>48 hours</time_frame>
    <description>Decreased post-operative pain scores associated with use of multimodal analgesia</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Multimodal Analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multimodal analgesia</intervention_name>
    <description>Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac</description>
    <arm_group_label>Multimodal Analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years

          -  American Society of Anesthesiologist Physical Status Classification 1-3

          -  Undergoing surgery requiring a rectus sheath block

        Exclusion Criteria:

          -  American Society of Anesthesiologist Physical Status Classification of 4 or beyond

          -  history of opiate of illicit substance abuse, chronic pain, or neurological
             dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emery N Brown, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin C Work</last_name>
    <phone>6177249857</phone>
    <email>ework@mgh.harvard.edu</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Emery Brown</investigator_full_name>
    <investigator_title>Director, Neuroscience Statistics Research Laboratory</investigator_title>
  </responsible_party>
  <keyword>multimodal</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>ketorolac</keyword>
  <keyword>pain management</keyword>
  <keyword>opioid sparing</keyword>
  <keyword>analgesia</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

